Executive Summary
The IPO Pipeline stream for 2026-11-03 contains a single filing: ADC Therapeutics SA's Form S-4 proposing redomiciliation from Switzerland to Delaware with continued NYSE listing under the ticker ADCT. The filing is a corporate-structure event rather than a new IPO or follow-on offering, so it sits at the edge of the stream's focus on registration activity.
Management's stated rationale centers on reduced duplicative regulatory costs, alignment with a predominantly U.S. operating base and investor base, Delaware corporate law flexibility, removal of Swiss limits on share issuance and preemptive rights, and elimination of PFIC exposure for U.S. holders. Because the enriched period-over-period, insider, capital allocation, and financial ratio fields are not populated for this filing, no cross-company trend or outlier analysis is possible. The transaction carries execution risk tied to shareholder approval, Swiss creditor, tax and Lex Koller rulings, and subsidiary restructuring, with a June 30, 2027 outside date. Sentiment is neutral and materiality is moderate at 6/10.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior US IPO Pipeline SEC S-1 Filings digest from November 02, 2026.
Investment Signals (2)
- ADC Therapeutics SA ↓ (BULLISH)▲
Redomiciliation to Delaware cites elimination of PFIC risk for U.S. holders and removal of Swiss share-issuance and preemptive-rights limits, a structural positive for capital-raising flexibility
- ADC Therapeutics SA ↓ (NEUTRAL)▲
Filing is neutral on sentiment with no enriched period comparisons, insider activity, or capital allocation data disclosed, so no quantitative directional signal can be extracted
Risk Flags (3)
-
Transaction is contingent on shareholder approval, Swiss creditor, tax and Lex Koller rulings, and subsidiary restructuring; failure to satisfy conditions by the June 30, 2027 outside date terminates the deal
-
Intercompany sale of certain IP to ADC Therapeutics America, Inc. and transfer of employees and agreements to a new Swiss subsidiary create tax, transfer-pricing and operational complexity during the transition
-
Multiple foreign regulatory and tax rulings (Swiss creditor, tax, and Lex Koller) are required, introducing timing uncertainty that may extend beyond expectations
Opportunities (2)
-
If completed, Delaware incorporation may broaden the investor base and simplify index and U.S. institutional eligibility for the NYSE-listed ADCT shares
-
Management cites reduced duplicative regulatory costs from dual Swiss and U.S. compliance, a potential margin tailwind not yet quantified in the filing
Sector Themes (1)
- Cross-Border Redomiciliation to U.S.◆
ADC Therapeutics' move from Switzerland to Delaware reflects a broader pattern of non-U.S. issuers with predominantly U.S. operations consolidating under Delaware law to reduce dual-jurisdiction costs and PFIC exposure for U.S. holders; a single filing limits aggregate measurement
Watch List (3)
-
Vote on Redomiciliation, Constitutive Documents and Discharge Proposals; date to be set by the S-4 effectiveness process
-
Pending Swiss creditor, tax and Lex Koller determinations; monitor for approval or objection before the June 30, 2027 outside date
-
Completion of the IP sale to ADC Therapeutics America, Inc. and employee transfer to the new Swiss subsidiary as a gating condition
Filing Analyses
(1)
03-11-2026
ADC Therapeutics SA filed a Form S-4 registration statement on November 3, 2026 for a proposed redomiciliation from Switzerland to Delaware, under which the company would become ADC Therapeutics, Inc. and continue trading on the NYSE as ADCT. Management cites reduced duplicative regulatory costs, closer alignment with its predominantly U.S. operations and investor base, Delaware corporate law flexibility, and removal of Swiss limits on share issuance and preemptive rights, as well as elimination of PFIC risk for U.S. holders. The transaction remains subject to shareholder approval, Swiss creditor, tax and Lex Koller rulings, subsidiary restructuring, and an outside date of June 30, 2027.
- · Shareholders will vote on the Redomiciliation Proposal, Constitutive Documents Proposal and Discharge Proposal at a shareholder meeting
- · Conditions include intercompany sale of certain IP from ADC Therapeutics SA to ADC Therapeutics America, Inc. and transfer of employees and agreements to a new Swiss subsidiary
- · Transaction will not be consummated if conditions are not satisfied by June 30, 2027
- · No changes expected to the board of directors or executive officers
- · Principal executive offices will move to 430 Mountain Avenue, New Providence, New Jersey; registered agent is The Corporation Trust Company
- · No material accounting effect or change in carrying amount of consolidated assets and liabilities; no pro forma financial statements included
Get daily alerts with 2 investment signals, 3 risk alerts, 2 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: US IPO Pipeline SEC S-1 Filings
🇺🇸 More from United States
View all →November 04, 2026
US Pre-Market SEC Filings Roundup — November 04, 2026
US Pre-Market SEC Filings Roundup
November 03, 2026
US Pre-Market SEC Filings Roundup — November 03, 2026
US Pre-Market SEC Filings Roundup
November 03, 2026
S&P 500 Technology Sector SEC Filings — November 03, 2026
S&P 500 Technology Sector SEC Filings
November 03, 2026
US SEC Filings Daily Market Digest — November 03, 2026
US SEC Filings Daily Market Digest